Centene Corporation is a diversified, multi-national healthcare enterprise providing a comprehensive portfolio of innovative services including healthcare coverage for Medicaid, Medicare and the Health Insurance Marketplace. Centene also contracts with other healthcare and commercial organizations to provide specialty services for improved healthcare outcomes. We align the foundation of our purpose, transforming the health of the community, through enhancing patient health outcomes and lowering healthcare costs.

As healthcare expenditures rise, biosimilar drugs represent a clear opportunity to reduce healthcare costs while maintaining patient access to vital therapies. We request providers advocate for the use of biosimilar agents to align with the foundation of our purpose.

Biosimilars

**SAFE AND EFFECTIVE**
Biosimilars are FDA-approved, safe and effective medicines that are highly similar to existing biologic medicines.¹

The FDA regulates biosimilar manufacturing to ensure they scientifically demonstrate safety and effectiveness while showing no clinically meaningful differences.¹

**INCREASE PATIENT ACCESS**
Biosimilar adoption increases access and treatment options for patients as additional agents continue to enter the market.

**COST SAVING**
With increased availability, healthcare providers can potentially purchase these medicines at wholesale cost.

---


Prescriber’s Quick Reference Guide

Biosimilar Alternatives for Commonly Prescribed Biologics
# List of Biosimilar Alternatives for Biological Reference

## AVASTIN® (BEVACIZUMAB)
- **Biosimilar Alternative**: Mvasi (bevacizumab-awwb)
  - **Manufacturer**: Amgen Inc.

## ENBREL® (ETANERCEPT)
- **Biosimilar Alternative**: Eticovo (etanercept-ykro)*
  - **Manufacturer**: Samsung Bioepis Co., Ltd.
- **Biosimilar Alternative**: Erelzi (etanercept-szzs)*
  - **Manufacturer**: Sandoz Inc.

## HERCEPTIN® (TRASTUZUMAB)
- **Biosimilar Alternative**: Herzuma (trastuzumab-pkrb)
  - **Manufacturer**: CELLTRION, Inc.
- **Biosimilar Alternative**: Kanjinti (trastuzumab-anss)
  - **Manufacturer**: Amgen Inc.
- **Biosimilar Alternative**: Ogivri (trastuzumab-dkst)
  - **Manufacturer**: Mylan GmbH, Mylan Gm

## HUMIRA® (ADALIMUMAB)
- **Biosimilar Alternative**: Abrilada (adalimumab-afzb)+
  - **Manufacturer**: Pfizer Inc.
- **Biosimilar Alternative**: Zirabev (adalimumab-bvzr)
  - **Manufacturer**: Pfizer Inc.
- **Biosimilar Alternative**: Amjevita (adalimumab-atto)+
  - **Manufacturer**: Amgen Inc.
- **Biosimilar Alternative**: Cyltezo (adalimumab-adbm)+
  - **Manufacturer**: Boehringer Ingelheim Pharmaceuticals, Inc.

## NEULASTA® (PEGFILGRASTIM)
- **Biosimilar Alternative**: Fulphila (pegfilgrastim-jmdb)
  - **Manufacturer**: Mylan GmbH
- **Biosimilar Alternative**: Ontruzant (pegfilgrastim-dttb)*
  - **Manufacturer**: Samsung Bioepis Co., Ltd. and Merck Sharp & Dohme Corp., Samsung Bioepis Co., Ltd.
- **Biosimilar Alternative**: Trazimera (pegfilgrastim-qyyp)
  - **Manufacturer**: Pfizer Ireland Pharmaceuticals

## RITUXAN® (RITUXIMAB)
- **Biosimilar Alternative**: Ruxience (rituximab-pvvr)
  - **Manufacturer**: Pfizer Ireland Pharmaceuticals
- **Biosimilar Alternative**: Truxima (rituximab-abbs)
  - **Manufacturer**: CELLTRION, Inc.

## NEUPOGEN® (FILGRASTIM)
- **Biosimilar Alternative**: Nivestym (filgrastim-aafi)
  - **Manufacturer**: Pfizer Inc.
- **Biosimilar Alternative**: Zarxio (filgrastim-sndz)
  - **Manufacturer**: Sandoz Inc.

## REMICADE® (INFLIXIMAB)
- **Biosimilar Alternative**: Avsola (infliximab-axxq)*
  - **Manufacturer**: Amgen Inc.
- **Biosimilar Alternative**: Inflectra (infliximab-dyyb)
  - **Manufacturer**: Sandoz Inc.
- **Biosimilar Alternative**: Ixifi (infliximab-qbtx)*
  - **Manufacturer**: Pfizer Ireland Pharmaceuticals
- **Biosimilar Alternative**: Renflexis (infliximab-abda)
  - **Manufacturer**: Samsung Bioepis Co., Ltd. and Merck Sharp & Dohme Corp., Samsung Bioepis Co., Ltd.

## RITUXAN® (RITUXIMAB)
- **Biosimilar Alternative**: Retacrit (epoetin alfa-epbx)
  - **Manufacturer**: Pfizer, Inc.
Centene Corporation is a diversified, multi-national healthcare enterprise providing a comprehensive portfolio of innovative services including healthcare coverage for Medicaid, Medicare and the Health Insurance Marketplace. Centene also contracts with other healthcare and commercial organizations to provide specialty services for improved healthcare outcomes. We align the foundation of our purpose, transforming the health of the community, through enhancing patient health outcomes and lowering healthcare costs.

As healthcare expenditures rise, biosimilar drugs represent a clear opportunity to reduce healthcare costs while maintaining patient access to vital therapies. We request providers advocate for the use of biosimilar agents to align with the foundation of our purpose.

Biosimilars

SAFE AND EFFECTIVE
Biosimilars are FDA-approved, safe and effective medicines that are highly similar to existing biologic medicines.¹

The FDA regulates biosimilar manufacturing to ensure they scientifically demonstrate safety and effectiveness while showing no clinically meaningful differences.¹

INCREASE PATIENT ACCESS
Biosimilar adoption increases access and treatment options for patients as additional agents continue to enter the market.

COST SAVING
With increased availability, healthcare providers can potentially purchase these medicines at wholesale cost.